Nortriptyline 25mg Film-coated Tablets

País: Reino Unido

Língua: inglês

Origem: myHealthbox

Ingredientes ativos:

Nortriptyline Hydrochloride

Disponível em:

MEDREICH PLC

Código ATC:

N06AA10

DCI (Denominação Comum Internacional):

Nortriptyline Hydrochloride

Dosagem:

25mg

Forma farmacêutica:

Film-coated tablets

Via de administração:

Oral use

Unidades em pacote:

Blister pack sizes: 10 tablets, 30 tablets and 100 tablets

Tipo de prescrição:

POM - Prescription Only Medicine

Fabricado por:

MEDREICH PLC

Grupo terapêutico:

Antidepressant, tricyclic

Indicações terapêuticas:

Nortriptyline is indicated for the relief of symptoms of depression. It may also be used for the treatment of some cases of nocturnal enuresis.

Status de autorização:

Authorised

Data de autorização:

2015-03-26

Folheto informativo - Bula

6-7
20-25 
44-55
10
8-11
25-35 
55-77
10-20
Over 11
35-54
77-119
25-35
AGE (YEARS)
WEIGHT
DOSE (MG)
KG
LB
years with psychiatric conditions who were treated with an 
antidepressant.
If you have thoughts of harming or killing yourself at any time, 
contact your doctor or go to hospital straight away.
You may find it helpful to tell a relative or close friend that you
are 
depressed or have an anxiety disorder, and ask them to read this 
leaflet. You
might ask them to tell you if they think your depression 
or anxiety is getting worse, or if they are worried about changes
in 
your behaviour.
If any of these points apply to you, tell your doctor or pharmacist.
TAKING OTHER MEDICINES
You should tell your doctor if you are taking or have taken any 
medicines, including medicines obtained without a prescription.
The following medicines may interact with your Nortriptyline Tablets:
•  guanethidine, debrisoquine, bethanidine, clonidine (used to
treat 
high blood pressure);
•  barbiturates (used for anxiety or to make you feel sleepy);
•  alcohol (you should not drink alcohol);
•  fluoxetine (another antidepressant);
•  cimetidine (for heartburn and ulcers);
•  phenothiazines (for mental illness);
•  carbamazepine (for epilepsy);
•  propafenone, flecainide, encainide, quinidine (for heartbeat
disorders)
It may still be all right for you to be given
Nortriptyline Tablets. 
Your doctor will be able to decide what is suitable for you.
DRIVING AND USING MACHINES
Nortriptyline Tablets may affect alertness. Use caution when 
driving or operating heavy machinery until you’re aware of how 
this drug affects you. If
you feel Nortriptyline Tablets affect your 
ability to drive or use machines, tell your doctor immediately.
IMPORTANT INFORMATION ABOUT SOME OF THE INGREDIENTS OF 
NORTRIPTYLINE TABLETS
Nortriptyline Tablets contain lactose. If you are
lactose intolerant, 
contact your doctor before taking this medicine. Nortriptylin

Características técnicas

SUMMARY OF PRODUCT CHARACTERISTICS 

1 
NAME OF THE MEDICINAL PRODUCT 
Nortriptyline 25mg Film-coated Tablets 

2 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each film coated tablet contains Nortriptyline
Hydrochloride equivalent to 
Nortriptyline 25 mg.  
Also contains lactose monohydrate and sunset yellow.  
For full list of excipients refer to section 6.1. 

3 PHARMACEUTICAL 
FORM 
Film-coated Tablets 
Nortriptyline 25mg Tablets are orange colored, round biconvex,
debossed with ‘N’ on 
one side and ‘25’ on one side  

4 CLINICAL 
PARTICULARS 

4.1 THERAPEUTIC 
INDICATIONS 
Nortriptyline is indicated for the relief of symptoms of
depression. It may also be 
used for the treatment of some cases of nocturnal enuresis.

4.2 
POSOLOGY AND METHOD OF ADMINISTRATION 
For oral administration. 
_Adults_: The usual adult dose is 25mg three or four times
daily. Dosage should begin 
at a low level and be increased as required. Alternatively, the
total daily dose may be 
given once a day. When doses above 100mg daily are administered,
plasma levels of 
Nortriptyline should be monitored and maintained in the
optimum range of 50 to 
150ng/ml. Doses above 150mg per day are not recommended. 

Lower than usual dosages are recommended for elderly patients and
adolescents. 
Lower dosages are also recommended for outpatients than for
hospitalised patients 
who will be
under close supervision. The physician should initiate dosage
at a low 
level and increase it gradually, noting carefully the
clinical response and any evidence 
of intolerance. Following remission, maintenance medication may be
required for a 
longer period of time at the lowest dose that
will maintain remission. 

If a patient develops minor side-effects, the dosage should
be reduced. The drug 
should be discontinued promptly if adverse effects of a serious
nature or allergic